Vaxcyte appointed David McAvoy as Chief Legal Officer and Luis Jodar as Chief Medical Officer on August 31, 2026. The company narrowed its guidance for topline safety, tolerability, and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial, now expecting results by the end of October 2026 instead of the previously communicated fourth quarter. Vaxcyte is a clinical-stage vaccine innovation company developing high-fidelity vaccines for bacterial diseases.

Vaxcyte, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $284.3 million compared to $166.6 million in the prior year period. Research and development expenses increased to $267.9 million from $194.2 million due to higher manufacturing costs for PCV programs and clinical trial expenses. The company held approximately $2.5 billion in cash, cash equivalents, and investments as of June 30, 2026. Clinically, the VAX-31 adult Phase 3 OPUS trials are fully enrolled with 6,191 participants dosed; topline data from the pivotal OPUS-1 trial is expected in Q4 2026, while OPUS-2 and OPUS-3 results are anticipated in H1 2027. The company also initiated a Phase 1 study for VAX-A1 against Group A Streptococcus. Additionally, Dr. Moncef Slaoui and Dr. John Markels were appointed to the Board of Directors, replacing retiring members Jacks Lee and Dr. Heath Lukatch. Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect against bacterial diseases.

Heath Lukatch is retiring from the Board of Directors, effective July 16, 2026. Concurrently, John Markels was appointed to the Board as a Class II director, effective the same date, with terms to expire at the 2028 annual meeting. Vaxcyte, Inc. is a biotechnology company focused on developing advanced vaccine technology.

Jacks Lee retired from the Board of Directors effective June 17, 2026, and transitioned to a consulting role focused on global strategic supply and manufacturing operations. Moncef Slaoui was appointed as a Class II director, effective immediately, with a term expiring in 2028. Vaxcyte, Inc. is a biotechnology company developing vaccine candidates.